Donald R Vandevanter

List of Publications by Year in Descending Order

77 papers	3,221 citations	30 h-index	55 g-index
88 ext. papers	3,923 ext. citations	3.8 avg, IF	5.02 L-index

#	Paper	IF	Citations
77	Antimicrobial resistance: Concerns of healthcare providers and people with CF. *Journal of Cystic Fibrosis*, **2021**, 20, 407-412	4.1	3
76	Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis. *Journal of Cystic Fibrosis*, **2021**, 20, 257-263	4.1	3
75	Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials. *Journal of Cystic Fibrosis*, **2021**, 20, 39-45	4.1	4
74	Changes in symptom scores as a potential clinical endpoint for studies of cystic fibrosis pulmonary exacerbation treatment. *Journal of Cystic Fibrosis*, **2021**, 20, 36-38	4.1	2
73	Epidemiologic Study of Cystic Fibrosis: 25 years of observational research. *Pediatric Pulmonology*, **2021**, 56, 823-836	3.5	3
72	Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study. *Journal of Cystic Fibrosis*, **2021**, 20, 965-971	4.1	3
71	Management of chronic infection with inhaled levofloxacin in people with cystic fibrosis. *Future Microbiology*, **2021**, 16, 1087-1104	2.9	3
70	A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 204, 1295-1305	10.2	7
69	Building global development strategies for cf therapeutics during a transitional cftr modulator era. *Journal of Cystic Fibrosis*, **2020**, 19, 677-687	4.1	8
68	Finding the relevance of antimicrobial stewardship for cystic fibrosis. *Journal of Cystic Fibrosis*, **2020** , 19, 511-520	4.1	5
67	Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF). *Journal of Cystic Fibrosis*, **2020**, 19, 595-601	4.1	26
66	Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. *Journal of Cystic Fibrosis*, **2020**, 19, 370-375	4.1	10
65	Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis. *Pediatric Pulmonology*, **2020**, 55, 828-834	3.5	8
64	Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations. *Annals of the American Thoracic Society*, **2020**, 17, 1590-1598	4.7	5
63	Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review. *Journal of Cystic Fibrosis*, **2019**, 18, 236-243	4.1	40
62	Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities. *Annals of the American Thoracic Society*, **2019**, 16, 534-539	4.7	17
61	The use of antimicrobial susceptibility testing in pediatric cystic fibrosis pulmonary exacerbations. *Journal of Cystic Fibrosis*, **2019**, 18, 851-856	4.1	4

60	Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. *Clinical Infectious Diseases*, **2019**, 69, 1812-1816	11.6	33
59	CFTR modulator theratyping: Current status, gaps and future directions. *Journal of Cystic Fibrosis*, **2019**, 18, 22-34	4.1	110
58	Measures of Cystic Fibrosis Airway Microbiota during Periods of Clinical Stability. *Annals of the American Thoracic Society*, **2019**, 16, 1534-1542	4.7	12
57	Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis. *Annals of the American Thoracic Society*, **2018**, 15, 485-493	4.7	38
56	Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF. *Contemporary Clinical Trials*, **2018**, 64, 35-40	2.3	32
55	Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change. *Pediatric Pulmonology*, **2018**, 53, 43-49	3.5	5
54	Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis. *PLoS ONE*, **2018**, 13, e0194060	3.7	51
53	Treatment Setting and Outcomes of Cystic Fibrosis Pulmonary Exacerbations. *Annals of the American Thoracic Society*, **2018**, 15, 225-233	4.7	21
52	Defining antimicrobial resistance in cystic fibrosis. *Journal of Cystic Fibrosis*, **2018**, 17, 696-704	4.1	40
51	BMI fails to identify poor nutritional status in stunted children with CF. *Journal of Cystic Fibrosis*, **2017**, 16, 158-160	4.1	11
50	The challenges of maintaining momentum in CF drug development and approval - Commentary. *Journal of Cystic Fibrosis*, **2017**, 16, 170-171	4.1	1
49	Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. *Journal of Cystic Fibrosis*, **2017**, 16, 600-606	4.1	53
48	Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. *Journal of Cystic Fibrosis*, **2017**, 16, 592-599	4.1	48
47	Feasibility of placebo-controlled trial designs for new CFTR modulator evaluation. *Journal of Cystic Fibrosis*, **2017**, 16, 496-498	4.1	11
46	Relationship of Antibiotic Treatment to Recovery after Acute FEV Decline in Children with Cystic Fibrosis. *Annals of the American Thoracic Society*, **2017**, 14, 937-942	4.7	25
45	Comparison of FEV reference equations for evaluating a cystic fibrosis therapeutic intervention. *Pediatric Pulmonology*, **2017**, 52, 1013-1019	3.5	6
44	Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies. *Current Opinion in Pulmonary Medicine*, **2017**, 23, 530-535	3	7
43	Anti-Infective Therapies in Cystic Fibrosis. *Milestones in Drug Therapy*, **2017**, 153-169		

42	Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment. *Journal of Cystic Fibrosis*, **2016**, 15, 147-57	4.1	69
41	Potential for Therapeutic Benefit among Cystic Fibrosis Populations Excluded from Clinical Trials or Labeling of Marketed Therapies. *Annals of the American Thoracic Society*, **2016**, 13, 1890-1893	4.7	1
40	Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis. *Journal of Cystic Fibrosis*, **2016**, 15, 783-790	4.1	26
39	A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. *Journal of Cystic Fibrosis*, **2016**, 15, 495-502	4.1	44
38	Culture-Based and Culture-Independent Bacteriologic Analysis of Cystic Fibrosis Respiratory Specimens. *Journal of Clinical Microbiology*, **2016**, 54, 613-9	9.7	35
37	Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. *Journal of Cystic Fibrosis*, **2016**, 15, 634-40	4.1	24
36	Forced Expiratory Volume in 1 Second Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function. *Journal of Pediatrics*, **2016**, 169, 116-21.e2	3.6	33
35	IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis. *Journal of Cystic Fibrosis*, **2016**, 15, 372-9	4.1	31
34	Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes. *Journal of Cystic Fibrosis*, **2015**, 14, 370-5	4.1	21
33	In Vitro Antibiotic Susceptibility of Initial Pseudomonas aeruginosa Isolates From United States Cystic Fibrosis Patients. *Journal of the Pediatric Infectious Diseases Society*, **2015**, 4, 151-4	4.8	6
32	Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site. *Pediatric Pulmonology*, **2015**, 50, 431-40	3.5	33
31	Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis. *Journal of Cystic Fibrosis*, **2015**, 14, 763-9	4.1	30
30	Clinical applications of pulmonary delivery of antibiotics. *Advanced Drug Delivery Reviews*, **2015**, 85, 1-6	18.5	37
29	Decline in lung function does not predict future decline in lung function in cystic fibrosis patients. *Pediatric Pulmonology*, **2015**, 50, 856-62	3.5	13
28	Use of ibuprofen to assess inflammatory biomarkers in induced sputum: Implications for clinical trials in cystic fibrosis. *Journal of Cystic Fibrosis*, **2015**, 14, 720-6	4.1	43
27	A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. *Journal of Cystic Fibrosis*, **2015**, 14, 507-14	4.1	51
26	Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. *Pediatric Pulmonology*, **2014**, 49, 650-8	3.5	73
25	Improvements in lung function and height among cohorts of 6-year-olds with cystic fibrosis from 1994 to 2012. *Journal of Pediatrics*, **2014**, 165, 1091-1097.e2	3.6	20

24	Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995-2005. *Journal of Cystic Fibrosis*, **2013**, 12, 332-7	4.1	16
23	Evidence of diminished FEV1 and FVC in 6-year-olds followed in the European Cystic Fibrosis Patient Registry, 2007-2009. *Journal of Cystic Fibrosis*, **2013**, 12, 786-9	4.1	7
22	Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. *Pediatric Pulmonology*, **2013**, 48, 666-73	3.5	82
21	Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. *Journal of Cystic Fibrosis*, **2012**, 11, 405-11	4.1	83
20	Decade-long bacterial community dynamics in cystic fibrosis airways. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 5809-14	11.5	431
19	Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease. *Clinical Investigation*, **2012**, 2, 163-175		28
18	Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?. *Respiratory Medicine*, **2011**, 105 Suppl 2, S9-17	4.6	19
17	Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis. *Respiratory Medicine*, **2011**, 105 Suppl 2, S18-23	4.6	14
16	Tobramycin administered by the TOBI( ) Podhaler( ) for persons with cystic fibrosis: a review. *Medical Devices: Evidence and Research*, **2011**, 4, 179-88	1.5	38
15	Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. *Respiratory Research*, **2010**, 11, 137	7.3	43
14	Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. *Pediatric Pulmonology*, **2010**, 45, 1156-66	3.5	34
13	Trends in the use of routine therapies in cystic fibrosis: 1995-2005. *Pediatric Pulmonology*, **2010**, 45, 1167-72	3.5	47
12	Characterizing aggressiveness and predicting future progression of CF lung disease. *Journal of Cystic Fibrosis*, **2009**, 8 Suppl 1, S15-9	4.1	41
11	Trends in the clinical characteristics of the U.S. cystic fibrosis patient population from 1995 to 2005. *Pediatric Pulmonology*, **2008**, 43, 739-44	3.5	17
10	First bacterial infection as an alternative clinical end point for regulatory approval of agents targeting the primary cystic fibrosis defect. *Journal of Pediatrics*, **2005**, 147, 332-4	3.6	
9	How much do Pseudomonas biofilms contribute to symptoms of pulmonary exacerbation in cystic fibrosis?. *Pediatric Pulmonology*, **2005**, 39, 504-6	3.5	46
8	Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. *Pediatric Pulmonology*, **2004**, 38, 314-20	3.5	105
7	Determination of polymyxin E1 in rat plasma by high-performance liquid chromatography. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2003**, 789, 365-72	3.2	17

6	A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. *Nature*, **2000** , 405, 962-6	50.4	827
5	Electrophoretic isolation of extrachromosomal DNA from tumor cells. *Genes Chromosomes and Cancer*, **1995**, 12, 262-71	5	1
4	Y chromosome loss in chronic myeloid leukemia detected in both normal and malignant cells by interphase fluorescence in situ hybridization. *Genes Chromosomes and Cancer*, **1994**, 11, 141-5	5	15
3	Resolution of DNA fragments from 23 kilobases to 6 megabases by biphasic linear pulse ramping. *Nucleic Acids Research*, **1992**, 20, 1148	20.1	6
2	Trisomy 8 in primary esthesioneuroblastoma. *Cancer Genetics and Cytogenetics*, **1991**, 57, 133-6		27
1	Cystic fibrosis: definition, severity and impact of pulmonary exacerbations25-37		